Tandem Diabetes Care (TNDM) stock experienced a significant pre-market plunge of 16.61% on Thursday, following the release of the company's fourth-quarter and full-year 2024 financial results that missed analysts' expectations.
The medical device maker reported an adjusted operating loss of $30.2 million for Q4, wider than analysts' estimate of a $17.6 million loss. Additionally, the adjusted net loss for the quarter came in at $28.8 million, missing the consensus estimate of a $14.9 million loss. The disappointing results were primarily driven by weaker-than-expected sales and higher costs.
Looking ahead, Tandem Diabetes Care provided a gloomy outlook for the current year, further weighing on investor sentiment. The company expects an adjusted net loss of $1.20 per share on revenue of $1.01 billion for 2025, falling short of analysts' projections.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.